In addition, no mutation of KRAS is found in other pancreatic tumors and cholangiocarcinoma (i.e., different from PDAC); the latter result reinforces the specificity of the ≪KRAS assay≫ for PDAC [15,28]. Here, KRAS is linked to cholangiocarcinoma.